Breaks Categories: News

ThursdayJun 05, 2025 9:50 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present Promising Glioblastoma Data at Brain Tumor Biotech Summit

CNS Pharmaceuticals (NASDAQ: CNSP) announced that Chief Medical Officer Sandra Silberman, M.D., Ph.D., will present at the Brain Tumor Biotech Summit hosted by Lenox Hill Hospital’s Department of Neurosurgery on June 5, 2025. Her presentation, titled "The Future and Promise of TPI 287," will highlight CNS’s brain-penetrating taxane candidate, which has shown efficacy in glioblastoma patients, including 3 complete and 9 partial responses in a Phase 1 trial. TPI 287, which has FDA Orphan Drug Designation for gliomas, pediatric neuroblastoma, and progressive supranuclear palsy, may offer a breakthrough in treating CNS tumors by effectively crossing the blood-brain barrier. To view…

Continue Reading

WednesdayJun 04, 2025 11:14 am

BioMedNewsBreaks — Soligenix Inc. (SNGX) Highlights HyBryte Progress in CTCL via New Podcast Featuring Dr. Ellen Kim 

Soligenix (SNGX) is spotlighting new interim data on HyBryte(TM) (synthetic hypericin) for early-stage cutaneous T-cell lymphoma (CTCL) in a recent podcast hosted by the Cutaneous Lymphoma Foundation. Featured guest Dr. Ellen Kim, Principal Investigator of the ongoing investigator-initiated study and Director of the Penn Cutaneous Lymphoma Program, reported a 75% treatment success rate at 18 weeks and up to 85% improvement in patients treated through 54 weeks. The study builds on prior results from the Phase 3 FLASH trial and mirrors the design of the current FLASH2 confirmatory trial, now enrolling patients. Dr. Kim emphasized HyBryte’s safety and tolerability, with…

Continue Reading

TuesdayJun 03, 2025 9:20 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at Noble Capital Markets Emerging Growth Virtual Conference

Nutriband (NASDAQ: NTRB) announced that CEO Gareth Sheridan will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Thursday, June 5 at 4 p.m. ET. The session will feature a fireside-style Q&A open to live audience questions, with 1x1 meetings available for qualified investors. A webcast of the presentation will be accessible post-event on Nutriband’s website and Channelchek.com, where it will remain archived for 90 days. To view the full article, visit https://ibn.fm/2U9UL About Nutriband Inc. Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is an abuse-deterrent…

Continue Reading

MondayJun 02, 2025 9:20 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Posts Record Q1 Revenue, Advances AVERSA Fentanyl Development

Nutriband (NASDAQ: NTRB) reported first-quarter revenue of $667,000, a 63% year-over-year increase driven by expanded kinesiology tape production through its Pocono Pharma subsidiary and growing retail presence at Target, Walmart, Walgreens, and CVS. The company continues to prioritize shareholder value by scaling Pocono’s output through penetration pricing strategies while advancing development of AVERSA Fentanyl, an abuse-deterrent transdermal opioid patch. A newly formalized partnership with Kindeva Drug Delivery will support shared development costs in exchange for milestone payments as AVERSA moves toward regulatory approval. The product is projected to reach peak U.S. sales of $80 million to $200 million annually. To…

Continue Reading

FridayMay 30, 2025 10:17 am

BioMedNewsBreaks — Lantern Pharma Inc. (NASDAQ: LTRN) Highlights LP-184 Preclinical Success in Pediatric Brain Cancer ATRT

Lantern Pharma (NASDAQ: LTRN) reported strong preclinical results for LP-184 in atypical teratoid rhabdoid tumors (“ATRT”), a rare and aggressive pediatric brain cancer. Presented by Dr. Eric Raabe of Johns Hopkins at the Society for Neuro-Oncology's Pediatric Neuro-Oncology Conference, the data showed LP-184 significantly improved survival in two mouse models, with one model achieving a 345% increase in median survival (20 to 89 days, p<0.0001). LP-184 demonstrated potent anti-tumor activity across ATRT subtypes, high blood-brain barrier penetration, and a favorable safety profile. Lantern plans to launch a pediatric Phase I trial in late 2025 or early 2026, following the completion…

Continue Reading

FridayMay 30, 2025 9:20 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Q1 Revenue Growth Driven by CDMO Contracts, Net Loss Narrows

Scinai Immunotherapeutics (NASDAQ: SCNI) reported first quarter 2025 financial results, posting $586K in revenue, up from zero in the prior-year period, reflecting continued expansion of its CDMO business. R&D expenses declined to $1.3M from $1.6M, while marketing, general and administrative costs held steady at $500K. The company recorded a $1.6M net loss, improving from a $2.2M loss in Q1 2024, aided by reduced R&D and financial expenses. Cash and equivalents totaled $1M at quarter-end, down from $2M a year earlier. To view the full press release, visit https://ibn.fm/038wJ About Scinai Immunotherapeutics Ltd. Scinai is a biopharmaceutical company with two complementary…

Continue Reading

ThursdayMay 29, 2025 10:22 am

BioMedNewsBreaks — Alzamend Neuro, Inc. (NASDAQ: ALZN) Doses First Patient in Phase II Trial for Next-Gen Lithium Therapy AL001

Alzamend Neuro (NASDAQ: ALZN) announced the first patient has been dosed in its Phase II clinical trial of AL001, a novel lithium-based therapeutic designed to treat Alzheimer’s, bipolar disorder, major depressive disorder and PTSD. Conducted at Massachusetts General Hospital, the study in healthy subjects will evaluate AL001’s ability to deliver lithium more efficiently to the brain while minimizing systemic side effects, potentially eliminating the need for therapeutic drug monitoring.  Backed by promising preclinical data showing improved brain absorption and reduced blood lithium levels, AL001 could mark a breakthrough in neuropsychiatric care. The therapy aims to address long-standing safety challenges associated with…

Continue Reading

ThursdayMay 29, 2025 9:30 am

BioMedNewsBreaks — VERAXA Biotech AG to Present at ASCO and BIO 2025 Conferences

VERAXA Biotech AG, a cancer therapy innovator, and proposed de-SPAC target of Voyager Acquisition Corp. (NASDAQ: VACH), announced plans to attend the 2025 ASCO Annual Meeting and BIO International Convention. CEO Christoph Antz and the VERAXA leadership team will meet with potential partners and investors to highlight the Company’s Bi-Targeted Tumor-Associated Cytotoxicity (BiTAC) platform and its pipeline of nine bispecific ADC and T-cell engager programs. The team will be joined by Voyager and Cantor Fitzgerald representatives as VERAXA prepares for its anticipated NASDAQ listing later this year. The ASCO event will take place May 30–June 3 in Chicago, followed by…

Continue Reading

TuesdayMay 27, 2025 11:30 am

BioMedNewsBreaks — NextPlat Corp. (NASDAQ: NXPL) Announces Passing of CEO Charles M. Fernandez, Appoints Interim Leadership 

NextPlat (NASDAQ: NXPL, NXPLW) announced with deep sadness the sudden passing of Executive Chairman and CEO Charles M. Fernandez on May 24. Fernandez had led the company since July 2021. The Board has appointed Rodney Barreto, Chair of the Audit Committee, as Interim Chairman, and David Phipps, current President and CEO of Global Operations, as Interim CEO. Vice Chairman Doug Ellenoff expressed condolences, noting Fernandez’s dedication to family and the company. Barreto, a director since 2022, brings over 35 years of business and civic leadership, while Phipps previously led NextPlat through its early growth and Nasdaq listing. The company is…

Continue Reading

TuesdayMay 27, 2025 9:10 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) CEO Highlights Transdermal Pain Solution on BioMedWire Podcast

Nutriband (NASDAQ: NTRB) is featured in the latest episode of The BioMedWire Podcast, part of IBN’s expanding podcast network focused on biotech and pharmaceutical innovation. In a conversation with host Carmel Fisher, Nutriband Co-Founder and CEO Gareth Sheridan outlined the company’s focus on transdermal drug delivery systems, particularly in the underserved area of pain management. Sheridan emphasized the impact of the opioid crisis on patient access to effective medications, noting that the stigma and liability concerns surrounding opioids have left many pain patients without adequate care. He introduced AVERSA(TM), Nutriband’s internally developed platform designed to deter abuse of opioid patches…

Continue Reading